+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08245(LIG1 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08245(LIG1 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

The HTF9C antibody is a monoclonal antibody primarily used to detect the HTF9C protein, also known as heme-regulated eukaryotic initiation factor 2α kinase (HRI or EIF2AK1). This kinase plays a critical role in cellular stress responses, particularly in erythroid cells, where it regulates protein synthesis by phosphorylating the α-subunit of eukaryotic initiation factor 2 (eIF2α) under conditions of heme deficiency or oxidative stress. By modulating eIF2α activity, HTF9C helps balance global protein translation with the selective synthesis of stress-responsive proteins, ensuring cellular adaptation to environmental challenges.

Originally characterized in studies of erythroid differentiation and hemoglobin biosynthesis, HTF9C is implicated in diseases such as anemia, cancer, and neurodegenerative disorders linked to dysregulated stress signaling. The HTF9C antibody, often raised in mice, is widely utilized in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate HRI expression, localization, and function. Its specificity for HRI makes it valuable in distinguishing this kinase from other eIF2α kinases (e.g., PKR, PERK) in research models. Studies employing HTF9C have advanced understanding of translational control mechanisms in both physiological and pathological contexts, particularly in hematopoiesis and stress adaptation pathways.